Long-term use of oxcarbazepine oral suspension in childhood epilepsy: Open-label study

Journal of Child Neurology

Volumn 21, Issue 6, 2006, Pages 480-485

  Rufo Campos, Miguel ^a   Casas Fernández, Carlos ^b   Martínez Bermejo, Antonio ^c  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; OXCARBAZEPINE;

ADOLESCENT; ARTICLE; ATAXIA; BENIGN CHILDHOOD EPILEPSY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; FREQUENCY ANALYSIS; HUMAN; INFANT; INFORMED CONSENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; POLYPHARMACY; PRIORITY JOURNAL; SEIZURE; STATISTICAL SIGNIFICANCE; STRABISMUS; SUSPENSION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADMINISTRATION, ORAL; ADOLESCENT; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; SUSPENSIONS; TREATMENT OUTCOME;

EID: 33746077124     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.2310/7010.2006.00120     Document Type: Article

References (12)

1. Gilman JT, Duchowny M, Campo AE: Pharmacokinetic considerations in the treatment of childhood epilepsy. Pediatr Drugs 2003;5:267-277.
2. French JA, Kanner AM, Bautista J, et al: Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1261-1273.
3. French JA, Kanner AM, Bautista J, et al: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1252-1260
4. Serdaroglu G, Kurul S, Tutuncuoglu S, et al: Oxcarbazepine in the treatment of childhood epilepsy. Pediatr Neurol 2003;28:37-41.
5. Beydoun A: Monotherapy trials of new antiepileptic drugs. Epilepsia 1997;38(Suppl):21-31.
6. Sabers A, Moller A, Dam M, et al: Cognitive function and anticonvulsant therapy: Effect of monotherapy in epilepsy. Acta Neurol Scand 1995;92:19-27.
7. Bang LM, Karen LG: Oxcarbazepine: A review of its use in children with epilepsy. Pediatr Drugs 2003;5:557-573.
8. Tecoma ES: Oxcarbazepine. Epilepsia 1990;40(Suppl 5):S37-S46.
9. Walmil AW, Schmutz M, Porte C, et al: Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. Eur J Pharmacol 1994;271:301-308.
10. Ichikawa K, Koyama N, Kiguchi S, et al: Inhibitory effect of oxcarbazepine on high-frequency firing in peripheral nerve fibres. Eur J Pharmacol 2001;420:119-192.
11. Stefani A, Pisan A, De Murtras M, et al: Action of GP 47779, the active metabolite of oxcarbazepine on the corticostriatal system II: Modulation of high-voltage-activated calcium currents. Epilepsia 1995;36:997-1002.
12. Pariente-Khayat A, Tran A, Vauzelle-Kervuroedan F, et al: Pharmacokinetic of oxcarbazepine as add-on therapy in epileptic children, abstract. Epilepsia 1994;35(Suppl 8):119.